Literature DB >> 8490843

Prognostic significance of clinical and pathologic features in diffuse large B-cell lymphoma.

H Nakamine1, R G Bagin, J M Vose, M A Bast, P J Bierman, J O Armitage, D D Weisenburger.   

Abstract

BACKGROUND AND METHODS: The diffuse large cell non-Hodgkin lymphomas are a heterogeneous group of neoplasms that are potentially curable. To identify important predictors of clinical outcome, the authors evaluated the clinical and pathologic features of 114 patients with newly diagnosed diffuse large B-cell lymphoma who were uniformly staged and treated with curative intent. The authors were particularly interested in determining whether any pathologic features added to the ability of the clinical features to predict patient survival.
RESULTS: Several clinical and pathologic features were found to be associated with survival by univariate analysis. However, multivariate analysis disclosed that only the stage of disease and the symptom status were significantly associated with survival. Low stage and lack of B symptoms were favorable indicators of overall survival and failure-free survival.
CONCLUSIONS: The authors suggest that the evaluation of pathologic features in diffuse large B-cell lymphoma has little prognostic utility and recommend that the pathology evaluation be limited to features that are useful for diagnostic purposes.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8490843     DOI: 10.1002/1097-0142(19930515)71:10<3130::aid-cncr2820711039>3.0.co;2-r

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  4 in total

1.  Phase II study of cyclophosphamide, doxorubicin, vincristine, prednisolone (CHOP) therapy for newly diagnosed patients with low- and low-intermediate risk, aggressive non-Hodgkin's lymphoma: final results of the Japan Clinical Oncology Group Study, JCOG9508.

Authors:  Yoshitoyo Kagami; Kuniaki Itoh; Kensei Tobinai; Haruhiko Fukuda; Kiyoshi Mukai; Takaaki Chou; Chikara Mikuni; Tomohiro Kinoshita; Noriyasu Fukushima; Yoshio Kiyama; Takayo Suzuki; Tsuneo Sasaki; Yuko Watanabe; Kunihiro Tsukasaki; Tomomitsu Hotta; Masanori Shimoyama; Michinori Ogura
Journal:  Int J Hematol       Date:  2012-06-03       Impact factor: 2.490

2.  De novo CD5-positive and Richter's syndrome-associated diffuse large B cell lymphomas are genotypically distinct.

Authors:  A Matolcsy; A Chadburn; D M Knowles
Journal:  Am J Pathol       Date:  1995-07       Impact factor: 4.307

3.  Prognostic Significance of Bcl-2 and p53 Protein Expressions and Ki67 Proliferative Index in Diffuse Large B-cell Lymphoma.

Authors:  Betül Bolat Küçükzeybek; Sadi Bener; Aylin Orgen Çallı; Tuğba Doğruluk Paksoy; Bahriye Payzin
Journal:  Turk J Haematol       Date:  2013-09-05       Impact factor: 1.831

4.  CD24 is a surrogate for 'immune-cold' phenotype in aggressive large B-cell lymphoma.

Authors:  Morihiro Higashi; Shuji Momose; Natsuko Takayanagi; Yuka Tanaka; Tomoe Anan; Takahisa Yamashita; Jun Kikuchi; Michihide Tokuhira; Masahiro Kizaki; Jun-Ichi Tamaru
Journal:  J Pathol Clin Res       Date:  2022-03-14
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.